Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
It will be the first time ER-100 technology they claim can reverse aging in cells has been tested on a human.
It will be the first time ER-100 technology they claim can reverse aging in cells has been tested on a human. This report comes from Wired. The story
Read Full Story at Wired →Why This Matters
If successful, this trial could mark a watershed moment in the convergence of longevity science and ophthalmology, proving that cellular rejuvenation isn’t just theoretical but clinically viable. Beyond restoring vision, it would validate a scalable framework for reversing age-related degeneration across multiple organs, potentially reshaping how society approaches aging itself.
Background Context
The field of epigenetic reprogramming—resetting cells to a more youthful state—has long been confined to animal studies due to ethical and technical barriers. Meanwhile, age-related macular degeneration remains the leading cause of blindness in older adults, with treatments only slowing progression rather than restoring function, creating a critical unmet need.
What Happens Next
Regulatory scrutiny will intensify as results emerge, with outcomes hinging on safety data and measurable improvements in retinal function. If the trial clears Phase 1, competitors will likely accelerate rival programs, while insurers and policymakers will face pressure to redefine coverage frameworks for experimental anti-aging interventions.
Bigger Picture
This trial reflects a broader inflection point where biotech is transitioning from disease management to proactive age reversal, mirroring the trajectory of oncology in the 20th century. As investment pours into geroscience, the distinction between ‘therapeutic’ and ‘enhancement’ may blur, challenging existing ethical and economic paradigms.
